A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study

Author:

Linssen Joachim1,Ermens Anthony2,Berrevoets Marvin3,Seghezzi Michela4,Previtali Giulia4,van der Sar-van der Brugge Simone2ORCID,Russcher Henk5,Verbon Annelies5,Gillis Judith6,Riedl Jürgen7,de Jongh Eva7,Saker Jarob1,Münster Marion1,Munnix Imke CA8,Dofferhof Anthonius8,Scharnhorst Volkher9,Ammerlaan Heidi9,Deiteren Kathleen10,Bakker Stephan JL11,Van Pelt Lucas Joost11ORCID,Kluiters-de Hingh Yvette3,Leers Mathie PG12,van der Ven Andre J13ORCID

Affiliation:

1. Sysmex Europe GmbH, Hamburg, Germany

2. Amphia Hospital, Breda, Netherlands

3. Elisabeth-Tweesteden Hospital, Tilburg, Netherlands

4. Hospital Papa Giovanni XXIII, Bergamo, Italy

5. Erasmus MC, University Medical Center, Rotterdam, Netherlands

6. Leiden University Medical Center, Leiden, Netherlands

7. Albert Schweitzer Hospital, Dordrecht, Netherlands

8. Canisius Wilhelmina Hospital, Nijmegen, Netherlands

9. Catharina Hospital, Eindhoven, Netherlands

10. University Hospital Antwerp, Antwerp, Belgium

11. University Medical Center Groningen, University of Groningen, Groningen, Netherlands

12. Zuyderland Medical Center, Sittard-Geleen, Netherlands

13. Radboud University Medical Center, Nijmegen, Netherlands

Abstract

COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration, and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723–0.781) increasing to 0.875 (95% CI 0.806–0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3